Related Experiment Video
Updated: Aug 21, 2026

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
Published on: July 9, 2016
Advancing Next-Generation Psychedelic Therapeutics through Selective 5‑HT2A Activation, Precision Aerosol Delivery,
Anna C Renner1, Robert B Kargbo2
1North Dakota State University, Fargo, North Dakota 58108-6050, United States.
None:
The psychedelic therapeutics field continues to evolve beyond classical hallucinogens toward integrated treatment platforms that combine optimized pharmacology, drug delivery, and clinical implementation. Recent patent applications disclose selective 5-HT2A receptor activators, precision aerosol delivery technologies for psychedelic compounds, and structured 5-MeO-DMT treatment regimens for depression. Together, these innovations illustrate a convergence toward scalable, safer, and clinically practical neuropsychiatric therapies that may reshape the future of serotonergic medicine.
More Related Videos
08:37Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
09:44Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
Related Concept Videos
CNS Stimulants: Psychedelic Agents
Drug Therapy
Antianxiety Medications
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Pharmacogenomics: Identification of New Drug Targets